The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Apellis Pharmaceuticals, Inc | COM | 037530106 | 72,482 | 3,294,654 | SH | DFND | 3,294,654 | 0 | 0 | ||
| Menlo Therapeutics Inc. | COM | 586858102 | 11,868 | 1,461,552 | SH | DFND | 1,461,552 | 0 | 0 | ||
| Nabriva Therapeutics PLC | SHS | G63637105 | 619 | 177,957 | SH | DFND | 177,957 | 0 | 0 | ||
| Verona Pharma PLC | SPONSORED ADS | 925050106 | 11,953 | 875,000 | SH | DFND | 875,000 | 0 | 0 | ||